HDAC6 and autoimmune disease: Although there are no human clinical studies as yet in inflammatory and autoimmune disease patients, similarly to class I HDACi in patients with cancer, HDAC6 inhibitors exhibit an improved safety profile compared with pan-HDACi [50].